Diversified Healthcare Trust (DHC) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 3% revenue increase and a significant 172% FFO growth, driven by operational improvements. Despite high interest rates on new financing, the company's asset sales and debt management strategies are positive. The Q&A reveals strategic asset dispositions and gradual occupancy growth, with no major negative trends. The reaffirmed guidance and improved debt metrics indicate stability. Overall, the sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
Key Financial Performance
Revenue $382.7 million, a 3% increase over last year. The increase was driven by continued recovery in the SHOP segment.
Adjusted EBITDAre $73.6 million, up 7% year-over-year. The increase was attributed to operational improvements.
FFO $18.6 million or $0.08 per share, a 172% year-over-year increase. This was due to strong sector fundamentals and capital expenditures in the SHOP segment.
Same-property SHOP NOI $37.4 million, an 18.5% year-over-year increase. This was driven by capital expenditures and strong sector fundamentals.
Average Monthly Rate Increased 5.4% year-over-year. This was primarily driven by annual rate increases and reductions in discounts and concessions.
Occupancy Increased 160 basis points year-over-year to 80.6%. This was due to improved sector fundamentals.
SHOP NOI Margin Improved 180 basis points year-over-year to 11.2% on a consolidated basis and 12.8% on a same-property basis. This was due to operational efficiencies.
Same-property NOI Margin for Five Star Communities 14.1%, up 170 basis points year-over-year. This was driven by operational improvements and pricing strategies.
RevPOR Increased 5.4% year-over-year. This was driven by annual rate increases and higher care level pricing.
ExpensePOR Increased 3.3% year-over-year. This was due to merit increases and filling open positions, partially offset by lower insurance costs.
Same-property Cash Basis NOI $71.2 million, an 11.2% increase year-over-year. This was driven by improvements in the SHOP segment.
Incremental NOI from Refreshes and Redevelopments $3.8 million during the quarter. This was due to completed refreshes and redevelopments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
SHOP sector performance: DHC reported a 6.2% increase in SHOP revenue, driven by a 5.4% increase in average monthly rate and a 160 basis point increase in occupancy to 80.6%. Same-property SHOP NOI increased by 18.5% year-over-year to $37.4 million, with a margin improvement of 180 basis points to 11.2%.
Medical Office and Life Science portfolio: Completed over 106,000 square feet of new and renewal leasing activity with weighted average rents 11.5% higher than prior rents. Active leasing pipeline includes 691,000 square feet, with potential for double-digit rent growth.
Asset sales and financing: DHC sold 5 unencumbered properties for a total of $25.2 million and completed $343 million of mortgage loans since March. A new $150 million credit facility was also obtained in June.
CapEx spending: Invested $34 million in Q2, including $29 million in SHOP communities and $5 million in Medical Office and Life Science portfolio. Reduced 2025 CapEx guidance to $140-$160 million.
Portfolio optimization: Active disposition pipeline includes 53 properties, with 49 under agreements or LOIs for $280 million. This includes 28 noncore SHOP communities and 21 Medical Office and Life Science assets. Proceeds will help retire 2026 notes and reduce leverage.
Debt management: Addressed 2025 bond maturity and reduced annual cash interest expense by $15 million. Strategy to address $641 million of January 2026 zero-coupon bond includes proceeds from dispositions, new financing, and liquidity position.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
SHOP segment performance: While the SHOP segment showed improvement, the NOI margin remains relatively low at 11.2% on a consolidated basis, indicating potential challenges in achieving higher profitability. Additionally, sequential SHOP revenue was flat, and expense increases are expected in Q3 and Q4 due to seasonality and additional days in the second half of the year.
Medical Office and Life Science portfolio: Same property occupancy decreased by 10 basis points to 89.8%, and 4% of annualized revenue is scheduled to expire by year-end 2025, with 1.9% being a known vacate. This could lead to revenue loss if vacancies are not filled promptly.
Debt and leverage: The company has a high net debt to adjusted EBITDAre ratio of 8.7x, which is above its target range of 6.5 to 7.5x. While progress is being made to address the 2026 bond maturity, the reliance on asset sales and new financing introduces execution risk.
Asset sales and disposition pipeline: The company is heavily reliant on asset sales to deleverage its balance sheet, with $280 million in dispositions under agreement or LOI. Delays or failures in these transactions could impact the ability to meet debt obligations and reduce leverage.
Capital expenditures: Although CapEx guidance has been reduced, the company still faces significant capital requirements, which could strain liquidity if operational cash flows do not improve as expected.
Interest rate environment: The weighted average interest rate on new financings is 6.5%, which is relatively high and could increase financial strain, especially if refinancing is needed in the future.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
SHOP NOI Guidance: Increased 2025 SHOP NOI guidance by $10 million at the midpoint to a range of $132 million to $142 million. This includes certain nonrecurring items that benefited NOI in the first half of the year. Expense increases are expected in Q3 and Q4 due to seasonality and increased number of days.
CapEx Guidance: Reduced 2025 CapEx guidance to $140 million to $160 million, a $10 million reduction from prior guidance.
Disposition Pipeline: Active disposition pipeline includes 53 properties, with 49 under agreements or Letters of Intent for $280 million. Majority of these sales are expected to transact in Q3 and Q4, providing funds to retire 2026 notes and reduce leverage.
Debt Maturity Strategy: Plan to address $641 million of January 2026 zero-coupon bond through $280 million of disposition proceeds, $300 million to $350 million of new financing expected in Q3, and existing liquidity. Option to extend bond maturity to January 2027 if needed.
Medical Office and Life Science Portfolio Outlook: Active leasing pipeline of 691,000 square feet, with 246,000 square feet as new absorption. Potential for double-digit rent growth and increased occupancy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What notable one-time items impacted 2Q '25 results and how might they affect the model going forward?
A:The majority of the NOI benefit came in 1Q due to insurance proceeds. There was a minor benefit in 2Q from PLGL insurance, but it was not as material as in 1Q. Seasonal increases in Q3 utilities and additional costs related to salaries and benefits are expected.
Q:Was the CapEx guidance change tied solely to reductions in SHOP CapEx or other factors?
A:The change was due to multiple factors, including dispositions, year-to-date spend comparisons, and tenant-managed leasing fluctuations in the MOB and Life Science portfolio. The range was tightened based on these factors.
Q:Are there any additional asset dispositions expected beyond the current pipeline under PSA and LOI?
A:The $280 million in PSA and LOI dispositions are targeted for Q3 and Q4. There are four additional properties (two MOB/Life Science and two SHOP) worth $20 million that may close in late Q4 or Q1 '26. This will conclude the broader asset disposition phase, transitioning to strategic capital recycling in 2026.
Q:Why did Five Star assets outperform other SHOP properties, and does this change the portfolio strategy?
A:Five Star's performance is attributed to improvements in its business model, team, and operating platform, as well as capital investments in its properties. Many Five Star properties are in primary markets, providing additional benefits. The portfolio strategy remains focused on both Five Star and other properties, with upside potential in the latter.
Q:Will occupancy build gradually or spike towards the end of the year?
A:Occupancy is expected to build gradually, targeting a year-end spot occupancy of about 82.5%. Seasonal trends and inflows/outflows from dispositions will influence this number.
Q:What was the nonrecurring benefit in 2Q, and where was it included in the P&L?
A:The nonrecurring benefit in 2Q was $1 million related to PLGL insurance, included in SHOP NOI on the expense side.
Q:What is the recurring CapEx per unit in the SHOP portfolio, and is the extra maintenance CapEx complete?
A:The recurring CapEx per unit is approximately $3,500. Deferred CapEx is mostly caught up, and no additional heavy maintenance CapEx years are expected.
Q:What is the nature of the new debt financing expected in 3Q?
A:The new debt financing of $300 million to $350 million is being considered in the form of secured or unsecured financing, but it is not expected to be on SHOP communities. More details will be provided in the coming months.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the exact nature of the new debt financing, stating only that it could be secured or unsecured and not on SHOP communities. Additionally, while they mentioned a $1 million nonrecurring benefit in 2Q, they did not elaborate on its broader implications for the financial model.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Albert Carroll
CEO Managing
CFO Massocca
Carroll RBC
Conference Instructions
DHC belief
DHC combination
DHC property
DHC result
Division Albert
Division Conference
GA expense
Medical Office
Murphy Manager
NOI increase
Office Life
Research Division
Science portfolio
Science property
balance sheet
cash flow
community Medical
improvement SHOP
incentive fee
increase SHOP
increase property
point increase
potential
price
property SHOP
sector
spending
DHC Transcript
Diversified Healthcare Trust (DHC) Q1 2026 Earnings Call Transcript
Positive5-5
The earnings report shows strong financial performance, with key metrics exceeding expectations, such as Normalized FFO and Adjusted EBITDAre. The company is experiencing NOI growth across segments and improving margins, which are positive indicators. The Q&A section provides additional insights into strategic investments and cost management, with management reaffirming guidance despite some uncertainties. The focus on ROI and reduced leverage adds to the positive sentiment. Overall, the financial health and strategic direction suggest a positive stock price movement.
Diversified Healthcare Trust (DHC) Q4 2025 Earnings Call Transcript
Positive2-24
The earnings call reflects positive financial performance with significant improvements in NOI margins and leverage reduction. The strategic focus on operational performance and disciplined capital spending is promising. While the Q&A revealed some uncertainties, such as unclear timelines for reopening wings and acquisition strategies, the overall outlook remains optimistic. The positive elements, including strong occupancy and pricing momentum, outweigh the minor concerns, supporting a positive sentiment.
Diversified Healthcare Trust (DHC) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call highlights positive financial performance with increased revenues, NOI, and occupancy across various segments. Despite temporary labor cost increases, the company maintains strong guidance and expects favorable transitions. The Q&A section reveals management's confidence in achieving targets and mitigating risks. The increase in SHOP NOI guidance and active disposition pipeline further support a positive outlook. However, the lack of specific details on potential revenue disruptions and disposition delays warrants caution. Overall, the sentiment leans towards positive due to strong financial metrics and optimistic guidance.
Diversified Healthcare Trust (DHC) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call highlights strong financial performance with a 3% revenue increase and a significant 172% FFO growth, driven by operational improvements. Despite high interest rates on new financing, the company's asset sales and debt management strategies are positive. The Q&A reveals strategic asset dispositions and gradual occupancy growth, with no major negative trends. The reaffirmed guidance and improved debt metrics indicate stability. Overall, the sentiment is positive, suggesting a potential stock price increase of 2% to 8% over the next two weeks.
DHC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
